TipRanks on MSN2d
GSK downgraded to Hold from Buy at JefferiesJefferies analyst Peter Welford downgraded GSK (GSK) to Hold from Buy with a price target of $39.50, down from $53. The firm ...
Q3 2024 Earnings Call Transcript November 7, 2024Dynavax Technologies Corporation beats earnings expectations.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback